The Evidence Gap We Can No Longer Ignore
During my tenure as Maryland’s Medical Cannabis Commissioner, I observed a striking paradox: thousands of patients were accessing cannabis for pain management through state programs, yet we had minimal standardized data on efficacy, optimal dosing, or long-term outcomes. Anecdotal success stories filled clinics, but the clinical trial infrastructure lagged dangerously behind patient adoption. This disconnect between clinical practice and evidence-based medicine remains one of the most pressing challenges in pain management today.
The landscape has shifted considerably. Over the past two years, Phase 2 and Phase 3 clinical trials have begun generating robust data on cannabinoid efficacy for neuropathic pain, inflammatory arthropathies, and post-operative pain management. A 2025 meta-analysis published in the Journal of Pain Research synthesized 47 randomized controlled trials and demonstrated that CBD-dominant formulations showed a 34% improvement in neuropathic pain scores compared to placebo, with particularly strong outcomes in patients who had failed traditional NSAIDs or opioid therapy.
Yet here’s what troubles me: we still lack consensus on cannabinoid standardization. THC:CBD ratios vary wildly across products and jurisdictions. Terpene profiles aren’t standardized. Delivery mechanisms—sublingual, inhalation, edible—produce dramatically different pharmacokinetics. When I see patients in my pain practices at Clearway Pain Solutions, they arrive with products purchased from various states or online sources, each claiming different therapeutic benefits based on anecdotal marketing rather than pharmacological science.
Why Standardization is a Clinical Imperative
In interventional spine and sports medicine, precision matters. When I prescribe a corticosteroid injection or perform a medial branch block, the dose, concentration, and delivery mechanism are standardized across medical practice. We know the expected pharmacokinetics, the duration of action, and the adverse event profile because we’ve conducted rigorous trials and established clinical protocols.
Cannabis-based therapeutics deserve the same rigor. The current fragmentation creates several problems: clinicians cannot reliably predict patient responses, adverse event monitoring remains anecdotal rather than systematic, and drug-drug interactions with traditional pain medications are poorly characterized.
The pharmaceutical industry is beginning to address this. GW Pharmaceuticals’ nabiximols (Sativex) has undergone rigorous standardization and now operates under conventional pharmaceutical oversight in multiple countries. Epidiolex, a pure CBD formulation, demonstrated such strong efficacy in seizure disorders that it achieved FDA approval with full standardized manufacturing protocols.
The Path Forward: Evidence-Driven Policy
We need a coordinated push across three domains. First, the National Institutes of Health and private research funding must accelerate large, multi-site clinical trials examining cannabinoid efficacy in chronic pain populations stratified by pain etiology. Second, state medical boards and pharmacy boards must establish cannabinoid standardization requirements—defining acceptable THC:CBD ratios for specific indications, establishing terpene testing standards, and requiring manufacturers to validate cannabinoid stability and purity. Third, medical educators must integrate evidence-based cannabis pharmacology into pain medicine curricula.
A Pragmatic Clinical Framework
For patients and physicians navigating this space today, I recommend a practical approach: treat cannabis-based therapeutics as you would any complementary therapy. Request patients bring their products for review so you can verify cannabinoid content and standardization. Start with CBD-dominant formulations for patients seeking pain relief without psychoactive effects. Establish baseline pain scores and function metrics, then reassess at 4 weeks. Monitor for interactions with existing medications, particularly those metabolized through CYP3A4 pathways.
Most importantly, recognize that standardized, evidence-based cannabis therapeutics represent a genuine advance in pain management—not a replacement for interventional procedures, physical medicine, or traditional pharmacotherapy, but a valuable addition to our armamentarium. The difference between today’s fragmented market and tomorrow’s standardized medicine is clinical rigor. That’s within our reach if we prioritize evidence over ideology.